Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 345 across all filing types
Latest filing 2025-07-07 Share Issue/Capital Cha…
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 95% confidence The document is a monthly regulatory disclosure required by the French AMF (Autorité des Marchés Financiers) regarding the total number of shares and voting rights. This type of filing is a standard regulatory requirement for listed companies in France to update the market on their capital structure. Since it does not fit into specific categories like 'Share Issue' (which would imply a change event) or 'Major Shareholding' (which would be a notification of a specific investor's stake), it falls under the general regulatory filing category.
2025-07-07 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from MaaT Pharma announcing an exclusive commercialization and licensing partnership with Clinigen for their drug Xervyteg. It details the financial terms of the agreement (initial payment, milestone payments, royalties), the strategic rationale, and information about the drug and the companies involved. This type of corporate announcement regarding business development, licensing, and commercial partnerships is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into more specific categories like M&A (which typically refers to corporate takeovers/mergers) or capital raising (which refers to equity/debt issuance).
2025-07-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic commercialization partnership and licensing agreement between MaaT Pharma and Clinigen. It details the financial terms of the deal (upfront payments, milestones, and royalties) and the strategic implications for the company's product pipeline. While it mentions a conference call, the document itself is a corporate announcement regarding a business transaction (M&A/Licensing/Partnership), which falls under the category of M&A Activity (TAR) as it relates to a significant corporate licensing and distribution agreement.
2025-07-02 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement detailing the results of MaaT Pharma's Annual General Meeting (AGM), including the approval of resolutions, voting percentages, and changes to the Board of Directors. Since it reports the specific outcomes of the shareholder votes and meeting proceedings, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2025-06-24 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release announcing the results of an Annual and Extraordinary General Meeting. It details the voting outcomes for various resolutions, including the approval of financial statements, compensation policies, and board appointments. Since the primary purpose is to report the official results of shareholder votes at a general meeting, it falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2025-06-24 English
Inside Information / Other news releases
AGM Information Classification · 95% confidence The document is a press release from MaaT Pharma providing a business update, pipeline highlights, and clinical trial milestones. It is not a formal financial report (10-K or IR), nor is it a transcript or a simple announcement of a report. It functions as a corporate update detailing strategic business activities, clinical trial progress, and regulatory milestones. Given the nature of the content—providing detailed updates on business strategy and operational milestones—it fits best under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-06-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.